Mohammad, Ramzi M <br/><br/>
Rituximab, Cyclophosphamide, Dexamethasone (RCD) regimen induces cure in WSU-WM xenograft model and a partial remission in previously treated Waldenstrom's macroglobulinemia patient.  [electronic resource] 

 -  Journal of drug targeting  Aug 2002 
 - 405-10 p.  digital 
<br/><br/> Publication Type: Case Reports; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>1061-186X 
<br/><br/><label>Standard No.: </label>10.1080/1061186021000001850  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Cell Division--drug effects<br/>Cell Line<br/>Cyclophosphamide--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Disease Models, Animal<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Mice<br/>Mice, Inbred ICR<br/>Mice, SCID<br/>Middle Aged<br/>Remission Induction<br/>Rituximab<br/>Waldenstrom Macroglobulinemia--drug therapy<br/>Xenograft Model Antitumor Assays